HANGZHOU TANGJI MEDICAL TECHNOLOGY CO., LTD.

杭州糖吉医疗科技股份有限公司

Develops medical devices for treating and managing metabolic diseases in China, including a gastric bypass stent (DJBL) for obesity, two other registered products, a digital health management platform, and 13 pipeline products.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Leased property
• Social insurance & housing fund
• Customer concentration
• Distribution model
• Single product, business line or region
• Government or SOE customers and tenders
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Seasonality and cyclicality
• Losses and path to profitability
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Inventory level and ageing
• Non-IFRS measures and adjustments
• Material share-based payments
• Chapter 18A biotech